<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sylvester, Bruce</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wijns, William</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Darapladib May Slow Expansion of Atherosclerotic Plaques</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">Darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), may slow expansion of the necrotic core of atherosclerotic plaques in patients with acute coronary syndrome or other symptomatic coronary diseases, according to mixed results from the Integrated Biomarker and Imaging Study-2 [IBIS-2; NCT00268996].</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>